Feasibility Study to Evaluate Renal Denervation Using Focused Ultrasound
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Kona Externally Focused Ultrasound Therapy
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Subject is at least 18 years of age.
- Subject has systolic blood pressure of 160 mmHg in average or greater.
- Subject has refractory, stable hypertension despite being treated with at least three hypertensive drugs.
- Subject has two functioning kidneys, defined as eGFR ≥ 45 ml/min.
- Subject has at least one renal artery on each side which is greater than 4mm.
Exclusion Criteria:
- Subject has hydronephrosis as seen on MRA or ultrasound.
- Subject has renal stenosis greater than 50% based on baseline MRA.
- Subject has a renal stent or other implant in the region.
- Subject has kidney stones which are symptomatic and/or greater than 1cm or in the discretion of the investigator may interfere with treatment.
- Subject has a history of abdominal surgery within the past six months.
- Subject has heterogeneities in the kidney such as large cysts or tumors which in the discretion of the investigator may interfere with treatment.
- Subject has active pyelonephritis or a history of pyelonephritis which in the discretion of the investigator may interfere with treatment.
- Subject has a history of myocardial infarction, unstable angina pectoris, or cerebrovascular accident within the last six months.
- Subject has hemodynamically significant valvular heart disease.
- Subject has an implantable cardioverter defibrillator, pacemaker, neurostimulator or other device incompatible with MRI.
- Subject has a body weight > 150 kilograms.
- Subject has a target treatment depth > 14 cm.
- Subject is pregnant, nursing or intends to become pregnant during the trial period.
- Subject is currently enrolled in other potentially confounding research.
- Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.
Sites / Locations
- Monash Medical Center
- St. Paul's Hospital
- St. Anne's University Hospital
- Nemocnice Na Homolee Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Renal Denervation Using Externally Focused Ultrasound Therapy
Arm Description
Outcomes
Primary Outcome Measures
Safety: Incidence of Adverse Events through 52 week follow-up
Safety will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation of bilateral treatment. Included in this assessment will be the proportion of subjects with any of the following outcomes: (1) death, or (2) medical morbidity, including but not limited to renal artery aneurysm, stenosis, significant deterioration of renal function, fistulae or ureteral stenosis.
Secondary Outcome Measures
Decrease in Blood Pressure
Clinical utility will be evaluated by assessing pre and post therapy systolic and diastolic blood pressure.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01704170
Brief Title
Feasibility Study to Evaluate Renal Denervation Using Focused Ultrasound
Official Title
A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound on Patients With Refractory Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
November 2012 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kona Medical Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is a prospective, multi-center trial wherein each included subject will receive the experimental externally focused ultrasound renal denervation therapy. It will be conducted on a maximum of fifty patients who meet the inclusion and exclusion criteria and have signed the informed consent form. Safety is the primary endpoint of this study and will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation. Clinical utility is the secondary endpoint of this study and will be evaluated by assessing pre and post therapy systolic and diastolic blood pressure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Renal Denervation Using Externally Focused Ultrasound Therapy
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Kona Externally Focused Ultrasound Therapy
Primary Outcome Measure Information:
Title
Safety: Incidence of Adverse Events through 52 week follow-up
Description
Safety will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation of bilateral treatment. Included in this assessment will be the proportion of subjects with any of the following outcomes: (1) death, or (2) medical morbidity, including but not limited to renal artery aneurysm, stenosis, significant deterioration of renal function, fistulae or ureteral stenosis.
Time Frame
One Year
Secondary Outcome Measure Information:
Title
Decrease in Blood Pressure
Description
Clinical utility will be evaluated by assessing pre and post therapy systolic and diastolic blood pressure.
Time Frame
12 and 24 weeks post therapy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is at least 18 years of age.
Subject has systolic blood pressure of 160 mmHg in average or greater.
Subject has refractory, stable hypertension despite being treated with at least three hypertensive drugs.
Subject has two functioning kidneys, defined as eGFR ≥ 45 ml/min.
Subject has at least one renal artery on each side which is greater than 4mm.
Exclusion Criteria:
Subject has hydronephrosis as seen on MRA or ultrasound.
Subject has renal stenosis greater than 50% based on baseline MRA.
Subject has a renal stent or other implant in the region.
Subject has kidney stones which are symptomatic and/or greater than 1cm or in the discretion of the investigator may interfere with treatment.
Subject has a history of abdominal surgery within the past six months.
Subject has heterogeneities in the kidney such as large cysts or tumors which in the discretion of the investigator may interfere with treatment.
Subject has active pyelonephritis or a history of pyelonephritis which in the discretion of the investigator may interfere with treatment.
Subject has a history of myocardial infarction, unstable angina pectoris, or cerebrovascular accident within the last six months.
Subject has hemodynamically significant valvular heart disease.
Subject has an implantable cardioverter defibrillator, pacemaker, neurostimulator or other device incompatible with MRI.
Subject has a body weight > 150 kilograms.
Subject has a target treatment depth > 14 cm.
Subject is pregnant, nursing or intends to become pregnant during the trial period.
Subject is currently enrolled in other potentially confounding research.
Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.
Facility Information:
Facility Name
Monash Medical Center
City
Melbourne
Country
Australia
Facility Name
St. Paul's Hospital
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
St. Anne's University Hospital
City
Brno
Country
Czech Republic
Facility Name
Nemocnice Na Homolee Hospital
City
Prague
Country
Czech Republic
12. IPD Sharing Statement
Learn more about this trial
Feasibility Study to Evaluate Renal Denervation Using Focused Ultrasound
We'll reach out to this number within 24 hrs